Retour

Watch Compare

Inventiva S.A.

Qualité des données : 17%

Également cotée sous IVEVF OTC

IVA

Nasdaq Manufacturing Chemicals

5,48 €

▲ 0,18 € (3,40%)

Cap. Boursière: 1,14 B

Company Details · Pierre Broqua

CEO: Pierre Broqua Employees: 114 IPO: May 07, 2019 Website

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

Prix

5,48 €

Cap. Boursière

1,14 B

Fourchette du Jour

5,16 € — 5,67 €

Fourchette 52 Semaines

2,85 € — 7,98 €

Volume

233 901

Ouverture 5,22 €

Moyenne 50J / 200J

6,20 €

11,58% below

Moyenne 50J / 200J

4,95 €

10,65% above

Quick Summary

Croissance

Revenue Growth (5Y)

N/A

Revenue (1Y)N/A

Earnings (1Y)N/A

FCF Growth (3Y)N/A

Qualité

Return on Equity

N/A

ROICN/A

Net MarginN/A

Op. MarginN/A

Sécurité

Debt / Equity

N/A

Current RatioN/A

Interest CoverageN/A

Valorisation

P/E Ratio

N/A

P/B RatioN/A

EV/EBITDAN/A

Dividend YieldN/A

Historique des Prix

Comparaison Sectorielle

vs médiane du secteur Manufacturing (44 pairs)

Métrique	Action	Médiane du Secteur
P/E	—	-2,0
P/B	—	5,1
ROE %	—	-51,0
Net Margin %	—	-150,2
Rev Growth 5Y %	—	9,3
D/E	—	0,3

All Fundamental Metrics

Growth
Revenue Growth (1Y)	N/A	Revenue Growth (3Y)	N/A
Earnings Growth (1Y)	N/A	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	N/A	Earnings Growth (5Y)	N/A
Profitability
Revenue (TTM)	N/A	Net Income (TTM)	N/A
ROE	N/A	ROA	N/A
Gross Margin	N/A	Operating Margin	N/A
Net Margin	N/A	Free Cash Flow (TTM)	N/A
ROIC	N/A	FCF Growth (3Y)	N/A
Safety
Debt / Equity	N/A	Current Ratio	N/A
Interest Coverage	N/A	Asset Turnover	N/A
Working Capital	N/A	Tangible Book Value	N/A
Dividends
Dividend Yield	N/A	Payout Ratio	N/A
Dividend Growth (3Y)	N/A	Dividend Growth (5Y)	N/A
Consecutive Div Years	N/A
Valuation
P/E Ratio	N/A	Forward P/E	N/A
P/B Ratio	N/A	P/S Ratio	N/A
PEG Ratio	N/A	Forward PEG	N/A
EV/EBITDA	N/A	Fwd EV/EBITDA	N/A
Forward P/S	N/A	Fwd Earnings Yield	N/A
FCF Yield	N/A
Market Cap	1,14 B	Enterprise Value	N/A
Per Share
EPS (Diluted TTM)	N/A	Revenue / Share	N/A
FCF / Share	N/A	OCF / Share	N/A
EPS CAGR (1Y)	N/A	EPS CAGR (5Y)	N/A
EPS CAGR (10Y)	N/A
Efficiency
CapEx / Revenue	N/A	FCF Conversion	N/A
SBC-Adj. FCF	N/A	Growth Momentum	N/A